Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LRAT | O95237 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16693701 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL23865565 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL23705072 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL11163399 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL23705099 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL24256226 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL24256547 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL23346141 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL22899188 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 | |
| SCHEMBL17054750 | 1.00 | LMNA (0.47) | LMNAKDM4EALOX15LGALS8HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LMNA 2955/4885KDM4E 4460/4885ALOX15 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.